IP Library Granted Patent US 8,575,165
Granted Patent B2
US 8,575,165 · App. 12/687,056 · Granted Nov 5, 2013

Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,575,165
App. No.
12/687,056
Granted
Nov 5, 2013
Kind
B2
Abstract

Methods for treating an inflammatory disorder and for inhibiting the production of IL-23 using 2,4-pyrimidinediamine compounds represented by formula (I):

Claims (19)

1. A method for inhibiting the production of IL-23, comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds according to the formula:

wherein X represents (CH 2 ) m , wherein m is an integer from 1 to 5, and wherein one or more CH 2 are optionally replaced with O, S or N(R 0 ), wherein R 0 represents H, C 1 -C 7 alkyl or C 3 -C 8 cycloalkyl;

Y represents N(R 1 ), O or S, wherein R 1 represents H, C 1 -C 7 alkyl or C 3 -C 8 cycloalkyl;

R 11 , R 12 , R 13 , and R 14 each independently represents C 1 -C 7 alkyl;

p represents 0 or 1;

R 2 represents H, C 1 -C 7 alkyl or C 2 -C 8 alkanoyl;

R 3 represents H, halogen, cyano, nitro, (C 1 -C 7 alkoxy)carbonyl, C 1 -C 7 alkyl, C 1 -C 7 haloalkyl, C 1 -C 7 alkoxy or C 1 -C 7 haloalkoxy;

R 4 represents H, C 1 -C 7 alkyl or C 2 -C 8 alkanoyl; and

R 5 represents a substituted aryl or heteroaryl.

2. The method of claim 1 , wherein the method further comprises stimulating the production of IL-10 and/or wherein the subject is a human.

3. A method for stimulating production of IL-10, comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds according to the formula:

wherein X represents (CH 2 ) m , wherein m is an integer from 1 to 5, and wherein one or more CH 2 are optionally replaced with O, S or N(R 0 ), wherein R 0 represents H, C 1 -C 7 alkyl or C 3 -C 8 cycloalkyl;

Y represents N(R 1 ), O or S, wherein R 1 represents H, C 1 -C 7 alkyl or C 3 -C 8 cycloalkyl;

R 11 , R 12 , R 13 , and R 14 each independently represents C 1 -C 7 alkyl;

p represents 0 or 1;

R 2 represents H, C 1 -C 7 alkyl or C 2 -C 8 alkanoyl;

R 3 represents H, halogen, cyano, nitro, (C 1 -C 7 alkoxy)carbonyl, C 1 -C 7 alkyl, C 1 -C 7 haloalkyl, C 1 -C 7 alkoxy or C 1 -C 7 haloalkoxy;

R 4 represents H, C 1 -C 7 alkyl or C 2 -C 8 alkanoyl; and

R 5 represents a substituted aryl or heteroaryl.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2010
From: GURURAJA, TARIKERE; PAYAN, DONALD G.; TSO, KIN; KINOSHITA, TAISEI; DING, RONGXIAN; SINGH, RAJINDER; YUNG, STEPHANIE; LI, HUI; MASUDA, ESTEBAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 024297/0232 →